Butyric Acid

Butyric Acid

SCHEMBL2453145

CCCC(=O)O.NC(=O)c1cc[nH]n1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
NNMT P40261 1/20 0.34
LMNA P02545 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PLA2G4B P0C869 6/20 0.33
HCAR2 Q8TDS4 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
PARP10 Q53GL7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL29441580 0.90 TSHR (0.37) NNMTLMNA
SCHEMBL1274 0.82
SCHEMBL28761094 0.82
Hydrochloric Acid SCHEMBL4602188 0.80 NNMT (0.39) NNMTLMNAL3MBTL1ADORA3PARP10
Bromide SCHEMBL21598344 0.80
Fluoride SCHEMBL28397310 0.80
Hydrochloric Acid SCHEMBL3825719 0.80
Methylsulfanylmethane SCHEMBL4600651 0.79 NNMT (0.40) NNMTLMNAADORA3PARP10
SCHEMBL9101778 0.78 HSD17B3 (0.41) L3MBTL1HCAR2CES2CES1
Formic Acid SCHEMBL2593165 0.75 NNMT (0.36) NNMTLMNAADORA3PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110295014-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2011-12-01 US disclosed
US-8022220-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2011-09-20 US disclosed
US-20100010227-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2010-01-14 US disclosed
US-7560561-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2009-07-14 US disclosed
EP-0877733-B1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES AMR TECHNOLOGY INC (US) 2006-08-09 EP disclosed
US-6974872-B2 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2005-12-13 US disclosed
US-20050272771-A1 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2005-12-08 US disclosed
EP-1362849-A2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2003-11-19 EP disclosed
US-20030171590-A1 Process for production of piperidine derivatives APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT 2003-09-11 US disclosed
US-6452011-B1 NON-SEDATING ANTI-HISTAMINE H1 ANTAGONIST ALBANY MOLECULAR RESEARCH, INC. 2002-09-17 US disclosed
US-6448406-B1 IMPROVED PROCESS FOR PREPARATION OF TERFENADINE CARBOXYLIC ACID METABOLITE AND CAREBASTINE DERIVATIVES; HISTAMINE H1 RECEPTOR BLOCKING AND CALCIUM ANTAGONISTS; RESPIRATORY, ALLERGIC, AND CARDIOVASCULAR DISEASE STATES ALBANY MOLECULAR RESEARCH, INC. 2002-09-10 US disclosed
US-6201124-B1 CONVERTING, WITH A PIPERIDINE COMPOUND, REGIOISOMERS UNDER NON-FRIEDEL-CRAFTS REACTION CONDITIONS ALBANY MOLECULAR RESEARCH, INC. 2001-03-13 US disclosed
EP-0877733-A4 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RES INC (US) 1999-03-31 EP disclosed
EP-0877733-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1998-11-18 EP disclosed
WO-1997022344-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1997-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295014-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES OR10J3, NR1H2, NR1H3 FFAR3 604/4885HDAC3 326/4885HDAC1 637/4885
US-20050272771-A1 Process for production of piperidine derivatives HRH4, CBR1, CBR3 FFAR3 999/4885HDAC3 389/4885HDAC1 576/4885
US-20030171590-A1 Process for production of piperidine derivatives NR4A1, NR4A2, NR5A2 FFAR3 1329/4885HDAC3 162/4885HDAC1 531/4885
US-20100010227-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES DDC, HPD, ALDH7A1 FFAR3 1698/4885HDAC3 457/4885HDAC1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.